Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanoscale activated carbon
- Development stage
- Preclinical
- Lead developer
- Modular Purification Systems
- Modality
- Nanoparticles → Drug Delivery Systems
01
Overview
Nanoscale activated carbon (also known as Nano-Slurry) is a nanoparticle sorbent designed to be added to the dialysate in hemodialysis systems. Developed by researchers at Temple University and its spinout Modular Purification Systems, it acts as an adsorbent to improve the efficiency of hemodialysis by rapidly removing uremic toxins such as creatinine and blood urea nitrogen (BUN). By incorporating nanoscale activated carbon into the dialysate, the system allows for the recirculation and reuse of dialysate, which significantly reduces water consumption for both in-center and home hemodialysis.
- Other names
- Nano-Slurry
Beyond the preview
Go deeper on nanoscale activated carbon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanoscale activated carbon.